Neoplasms

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

All Conditions

Rare Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Neoplasms by Histologic Type

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Participants diagnosed with multiple myeloma in complete, partial or very good partial remission per standard International Myeloma Working Group Criteria will complete neurocognitive tests and structural and functional rsfMRI (brain MRIs).

Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= \~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.

Structural Image

Functional Image

Evaluates auditory attention and working memory

Digit Span subtest

Brief Test of Attention

Assesses visual scanning, graphomotor speed, and setshifting

Trail Making Test (Parts A & B)

Assesses attention and susceptibility to interference

Auditory Consonant Trigrams Test

Controlled Oral Word Association Test

The HVLT-R is a test of verbal learning and recall.

Hopkins Verbal Learning Test-Revised

The Center for Epidemiological Study-Depression

A 13-item questionnaire designed to assess symptoms and concerns specific to the QOL of patients with fatigue

The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Version 4

Blood samples will be collected at each time point (pre-ASCT; 3-4 months and post-ASCT) to assess serum levels of inflammatory cytokines.

Blood draw

Denise Correa, PhD

The purpose of this study is to learn about possible changes in thinking (cognitive) abilities, such as memory skills, and in brain anatomy and function, in adults with multiple myeloma who are treated with high-dose chemotherapy followed by ASCT.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation	NCT03508765	Multiple Myelom...	Structural Imag... Functional Imag... Digit Span subt... Brief Test of A... Trail Making Te... Auditory Conson... Controlled Oral... Hopkins Verbal ... The Center for ... The Functional ... Blood draw	60 Years - 75 Years	Memorial Sloan Kettering Cancer Center
Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation	NCT03508765	Multiple Myelom...	Structural Imag... Functional Imag... Digit Span subt... Brief Test of A... Trail Making Te... Auditory Conson... Controlled Oral... Hopkins Verbal ... The Center for ... The Functional ... Blood draw	60 Years - 75 Years	Memorial Sloan Kettering Cancer Center

Spots Global Cancer Trial Database for trail making test (parts a & b)